Recombinant Chimeric (human/mouse) monoclonal antibody expressed in CHO binding to Human EGFR. This is a novel EGFR antibody that selectively targets a tumor-selective epitope suggesting that a mAb 806-based therapeutic would retain antitumor activity without the on-target toxicities associated with EGFR inhibition.
Figure 1 ABT-806 is more potent than cetuximab at inhibiting EGFRvIII tumor growth and pEGFR expression.
Total and pEGFR status in SN0199 tumors were assessed following treatment of mice with ABT-806 at 40 mg/kg. Antibodies were administered Q3D×2, with tumors harvested 72 hour after the final dose.
Figure 2 ABT-806 downregulates tumor wild-type EGFR and pEGFR in SCC15 tumors grown as implants in mice.
IHC images of representative samples derived from harvested tumors 120 hours after treatment. IHC results were obtained by semiquantitative assessment of the
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.